Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: A systematic literature review and regresrtsion analysis

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Fahrbach, Kyle ^a   Huelin, Rachel ^a   Martin, Amber L ^a   Kim, Edward ^b   Dastani, Homa B ^c   Rao, Stephen ^d   Malhotra, Manoj ^e  

^a EVIDERA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BRISTOL MYERS SQUIBB   (United States)

^d Cleveland Clinic Neurological Institute   (United States)

^e Questcor Pharmaceuticals Inc   (United States)

Author keywords

Disability progression; Relapse; Relapsing remitting multiple sclerosis; Secondary progressive multiple sclerosis; T2 lesions

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; DIRUCOTIDE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; HYDROLASE; IMMUNOGLOBULIN; INOSINE; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PREDNISONE;

ARTICLE; DATA BASE; DEMYELINATING DISEASE; DISABILITY; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; EMBASE; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HAPLOTYPE; HUMAN; LONG TERM CARE; MEDLINE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCINFO; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; RISK FACTOR;

BRAIN; CLINICAL TRIALS AS TOPIC; DISABLED PERSONS; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS;

EID: 84887667549     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-180     Document Type: Article

References (47)

1. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S, et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology 2002, 58:169-178. 10.1212/WNL.58.2.169, 11805241.
2. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, Laursen H. Demyelination versus remyelination in progressive multiple sclerosis. Brain 2010, 133:2983-2998. 10.1093/brain/awq250, 20855416.
3. Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol 2008, 255:280-287. 10.1007/s00415-008-0743-8, 18204919.
4. Rio J, Rovira A, Tintore M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008, 14:479-484. 10.1177/1352458507085555, 18562504.
5. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study: I: clinical course and disability. Brain 1989, 112(Pt 1):133-146.
6. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach. Neurology 2010, 75:302-309. 10.1212/WNL.0b013e3181ea15aa, 20574036.
7. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, Hill SR, Ward RL. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology 2006, 7:741-746. 10.1016/S1470-2045(06)70800-2, 16945769.
8. Ebers GC. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial: the IFNB multiple sclerosis study group. Neurology 1993, 43:655-661.
9. Ebers GC. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis: PRISMS (Prevention of Relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group. Lancet 1998, 352:1498-1504. 10.1016/S0140-6736(98)03334-0, 9820297.
10. Francis G. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001, 56:1496-1504.
11. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998, 50:398-402. 10.1212/WNL.50.2.398, 9484361.
12. Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Myhr KM, Sandberg-Wollheim M, Soelberg Sorensen P. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004, 75:706-710. 10.1136/jnnp.2003.010090, 1763573, 15090564.
13. Baumhackl U, Kappos L, Radue EW, Freitag P, Guseo A, Daumer M, Mertin J. A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis. Mult Scler 2005, 11:166-168. 10.1191/1352458505ms1132oa, 15794389.
14. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002, 59:1507-1517. 10.1212/01.WNL.0000032256.35561.D6, 12451189.
15. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, et al. Benefit of interferon (beta)-1a on MSFC progression in secondary progressive MS. Neurology 2002, 59:679-687. 10.1212/WNL.59.5.679, 12221157.
16. Coles AJ, Compston DAS, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801.
17. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001, 49:290-297. 10.1002/ana.64, 11261502.
18. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002, 359:1453-1460. 10.1016/S0140-6736(02)08430-1, 11988242.
19. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 2006, 113:283-287.
20. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis: Austrian immunoglobulin in multiple sclerosis study group. Lancet 1997, 349:589-593. 10.1016/S0140-6736(96)09377-4, 9057729.
21. Freedman MS, Francis GS, Sanders EA, Rice GP, O'Connor P, Comi G, Duquette P, Metz L, Murray TJ, Bouchard JP, et al. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 2005, 11:41-45. 10.1191/1352458505ms1126oa, 15732265.
22. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010, 362:416-426. 10.1056/NEJMoa0902533, 20089960.
23. Gonsette RE, Sindic C, D'Hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of inosine and interferon (beta) in relapsing-remitting multiple sclerosis (ASIIMS) trial. Mult Scler 2010, 16:455-462. 10.1177/1352458509360547, 20200198.
24. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T, Albrecht H, Basedow-Rajwich B, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025. 10.1016/S0140-6736(02)12023-X, 12504397.
25. Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 2009, 15:965-976. 10.1177/1352458509105229, 19465443.
26. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39:285-294. 10.1002/ana.410390304, 8602746.
27. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: the copolymer 1 multiple sclerosis study group. Neurology 1995, 45:1268-1276. 10.1212/WNL.45.7.1268, 7617181.
28. Kappos L. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998, 352:1491-1497. 10.1016/S0140-6736(98)10039-9, 9820296.
29. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249. 10.1212/01.wnl.0000237641.33768.8d, 16914693.
30. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401. 10.1056/NEJMoa0909494, 20089952.
31. Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 2010, 16:450-454. 10.1177/1352458509358909, 20150398.
32. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag BM. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008, 7:903-914. 10.1016/S1474-4422(08)70200-X, 18789766.
33. Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, Morino S, Morra VB, Bozzao A, Calo A, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997, 244:153-159. 10.1007/s004150050066, 9050955.
34. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, et al. 250 (mu)g or 500 (mu)g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009, 8:889-897. 10.1016/S1474-4422(09)70226-1, 19729344.
35. Panitch H. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004, 63:1788-1795.
36. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. 10.1056/NEJMoa044397, 16510744.
37. Ravnborg M, Sorensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholome E, Constantinescu CS, Beer K, Garde E, Sperling B. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 2010, 9:672-680. 10.1016/S1474-4422(10)70132-0, 20542736.
38. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923. 10.1056/NEJMoa044396, 16510745.
39. Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Sogaard LV, Olsen IC, Sandberg-Wollheim M. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009, 8:519-529. 10.1016/S1474-4422(09)70085-7, 19409854.
40. Van De Wyngaert FA, Beguin C, D'Hooghe MB, Dooms G, Lissoir F, Carton H, Sindic CJM. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurologica Belgica 2001, 101:210-216.
41. Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry 2011, 82:1344-1350. 10.1136/jnnp.2010.229724, 21436229.
42. Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011, 77:1551-1560. 10.1212/WNL.0b013e318233b240, 21975206.
43. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012, 380:1819-1828. 10.1016/S0140-6736(12)61769-3, 23122652.
44. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1829-1839. 10.1016/S0140-6736(12)61768-1, 23122650.
45. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M, Group AS. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012, 366:1000-1009. 10.1056/NEJMoa1104318, 22417253.
46. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012, 367:1087-1097. 10.1056/NEJMoa1206328, 22992072.
47. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012, 367:1098-1107. 10.1056/NEJMoa1114287, 22992073.